Skip to Content

Epigenomics AG EPGNF Stock Quote

| Rating as of


Last close prices updated as of Jan 20, 2023, 3:14 PM EST | USD
  • Last Close 1.33
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Investment Style Small Value
  • Day Range 1.33  –  1.33
  • Year Range 0.90  –  2.28
  • Market Cap 5.4434 Mil
  • Volume / Avg 1,260.0 /  8,885.1
  • Price / Sales 8.78
  • Price / Book 0.36
  • Forward Div Yield
  • Trailing Div Yield

Morningstar‘s Stock Analysis EPGNF

Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics EPGNF

Company Profile EPGNF

Business Description

Epigenomics AG is a molecular diagnostics company, focuses on developing and commercializing in vitro diagnostic liquid biopsy tests for the screening, early detection, and diagnosis of cancer. The company develops and markets procedures and devices for the production in quantity of particular epigenetic parameters such as DNA methylation patterns as well as the information technology bases necessary for their procurement and evaluation. It is engaged in the development of novel molecular diagnostic products for cancer. The company products include Epi proColon, Epi BiSKit, HCCBloodTest, and Epi proLung. The company operates in Europe, Asia, North America, and the Rest of the world.

Geneststrasse 5
Berlin, 10829, DEU
Industry Diagnostics & Research
Employees 36

FAQs for Epigenomics AG Stock

No. EPGNF does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

EPGNF’s market cap is 5.44 Mil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

EPGNF’s stock style is Small Value.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

EPGNF’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare EPGNF’s historical performance against its industry peers and the overall market.